Heart failure & cardiomyopathies
Socioeconomic Determinants of Vaccination Against Pneumococcus in 763 945 Patients with Heart Failure
Study context
- Population
- Patients with heart failure (HF) in the French Nationwide Health Claims Database, followed throughout 2020
- Participants
- 763,945 patients
- Outcome
- Factors associated with pneumococcal vaccination (≥1 dose of PCV13 as proxy)
- Follow-up
- Year 2020
Methodological detailsnationwide health claims database, multivariable logistic regression
- Nationwide health claims database
- Multivariable logistic regression
Main finding
As reported in the abstract
Receipt of ≥1 dose of PCV13 (multivariable logistic regression) · 2020
Odds ratio (CI)P value
Patients 76-85older age
0.71(0.67–0.74)
P < 0.0001Older than 85 years oldolder age
0.48(0.46–0.51)
P < 0.0001Women
0.916(0.903–0.929)
P < 0.0001Quintile Q5 of deprivation indexsocial deprivation
0.893(0.872–0.914)
P < 0.0001- Vaccination coverage for pneumococcus (PCV13)
- 12.6%
- Vaccination coverage for influenza
- 63.1%
Observational data: associations, not effects.
Further findings
Influenza vaccination coverage
- Influenza vaccination coverage
- 63.1%
Mean annual healthcare visits
- General practitioner
- 7.0
- Specialist
- 1.68
- Nurse
- 70.0
Original publication
Socioeconomic Determinants of Vaccination Against Pneumococcus in 763 945 Patients with Heart Failure. ESC Heart Fail. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →